Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from Lactobacillus casei in NC/Nga mice

Verfasser / Beitragende:
[Min-Soo Kim, Jin-Eung Kim, Yeo-Sang Yoon, Tai Kim, Jae-Gu Seo, Myung-Jun Chung, Do-Young Yum]
Ort, Verlag, Jahr:
2015
Enthalten in:
Applied Microbiology and Biotechnology, 99/17(2015-09-01), 7089-7099
Format:
Artikel (online)
ID: 605503060
LEADER caa a22 4500
001 605503060
003 CHVBK
005 20210128100609.0
007 cr unu---uuuuu
008 210128e20150901xx s 000 0 eng
024 7 0 |a 10.1007/s00253-015-6455-y  |2 doi 
035 |a (NATIONALLICENCE)springer-10.1007/s00253-015-6455-y 
245 0 0 |a Improvement of atopic dermatitis-like skin lesions by IL-4 inhibition of P14 protein isolated from Lactobacillus casei in NC/Nga mice  |h [Elektronische Daten]  |c [Min-Soo Kim, Jin-Eung Kim, Yeo-Sang Yoon, Tai Kim, Jae-Gu Seo, Myung-Jun Chung, Do-Young Yum] 
520 3 |a Atopic dermatitis (AD) is a chronic inflammatory skin disease, with a complex etiology encompassing immunologic responses. AD is frequently associated with elevated serum immunoglobulin (Ig) E levels and is exacerbated by a variety of environmental factors, which contribute to its pathogenesis. However, the etiology of AD remains unknown. Recently, reports have documented the role of lactic acid bacteria (LAB) in the treatment and prevention of AD in humans and mice. The LAB, Lactobacillus casei (LC), is frequently used in the treatment of AD. To identify the active component of LC, we screened fractions obtained from the ion exchange chromatography of LC extracts. Using this approach, we identified the candidate protein, P14. We examined whether the P14 protein has anti-atopic properties, using both in vitro and in vivo models. Our results showed that the P14 protein selectively downregulated serum IgE and interleukin-4 cytokine levels, as well as the AD index and scratching score in AD-like NC/Nga mice. In addition, histological examination was also effective in mice. These results suggest that the P14 protein has potential therapeutic effects and that it may also serve as an effective immunomodulatory agent for treating patients with AD. 
540 |a Springer-Verlag Berlin Heidelberg, 2015 
690 7 |a Atopic dermatitis  |2 nationallicence 
690 7 |a P14 protein  |2 nationallicence 
690 7 |a Immunoglobulin E  |2 nationallicence 
690 7 |a Interleukin-4  |2 nationallicence 
690 7 |a NC/Nga mouse  |2 nationallicence 
700 1 |a Kim  |D Min-Soo  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Kim  |D Jin-Eung  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Yoon  |D Yeo-Sang  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Kim  |D Tai  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Seo  |D Jae-Gu  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Chung  |D Myung-Jun  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
700 1 |a Yum  |D Do-Young  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
773 0 |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/17(2015-09-01), 7089-7099  |x 0175-7598  |q 99:17<7089  |1 2015  |2 99  |o 253 
856 4 0 |u https://doi.org/10.1007/s00253-015-6455-y  |q text/html  |z Onlinezugriff via DOI 
898 |a BK010053  |b XK010053  |c XK010000 
900 7 |a Metadata rights reserved  |b Springer special CC-BY-NC licence  |2 nationallicence 
908 |D 1  |a research-article  |2 jats 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-springer 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1007/s00253-015-6455-y  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kim  |D Min-Soo  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kim  |D Jin-Eung  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yoon  |D Yeo-Sang  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Kim  |D Tai  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Seo  |D Jae-Gu  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Chung  |D Myung-Jun  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Yum  |D Do-Young  |u R&D Center, Cell Biotech, Co., Ltd, 134 Gaegok-Ri Wolgot-Myeon, 415-872, Gimpo-Si, Gyeonggi-Do, Korea  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Applied Microbiology and Biotechnology  |d Springer Berlin Heidelberg  |g 99/17(2015-09-01), 7089-7099  |x 0175-7598  |q 99:17<7089  |1 2015  |2 99  |o 253